Ajanta Pharma Q2 FY2027: revenue up 33%, PAT up 49%

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

AJANTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.0%Reaction day

₹3462.40

prior close

₹3512.70

announcement price

In-mkt

timing

Nifty Midcap 150market-0.9%+0.9% vs market

Pharmaceuticals peers, median of 173sector-0.8%+0.8% vs sector

On the reaction day the stock moved 0.9 pts more than Nifty Midcap 150 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+1.2

15m

+1.8

30m

+1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.0-0.9+0.9-0.8+0.8

Next day

-2.0+0.3-2.3-0.7-1.3

-4.1+1.3-5.4-0.5-3.6

-4.0+2.9-6.9+0.4-4.3

-5.0+4.9-9.9+1.4-6.4

-4.7pendingpending+1.4-6.1

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ajanta Pharma reported Q2 FY2027 consolidated revenue of Rs 1,794 crore, up 33%, and PAT of Rs 388 crore, up 49%. Adjusted EBITDA rose 47% to Rs 543 crore, while margin improved to 30% from 27%. For H1, revenue grew 29% to Rs 3,420 crore and PAT rose 40% to Rs 722 crore. Growth was led by US generics and Africa institutional sales. The limited review found no material misstatement.

Likely market impact

Strong sales, profit and margin gains should support shareholder confidence and the stock, though future results depend on new launches and market growth.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹1,794 Cr	₹1,354 Cr	+32.5%
Operating profit	₹497.8 Cr	₹281.5 Cr	+76.8%
Profit after tax	₹388.1 Cr	₹260.2 Cr	+49.2%
EBITDA margin	30.5%	24.2%	+6.3 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.